Investing.com - Sellas Life Sciences (NASDAQ: SLS) reported first quarter EPS of $-0.23, $0.22 worse than the analyst estimate of $-0.02. Revenue for the quarter came in at $13M versus the consensus estimate of $13M.
Sellas Life Sciences's stock price closed at $1.01. It is down -4.72% in the last 3 months and down -19.20% in the last 12 months.
Sellas Life Sciences saw 3 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Sellas Life Sciences's stock price’s past reactions to earnings here.
According to InvestingPro, Sellas Life Sciences's Financial Health score is "weak performance".
Check out Sellas Life Sciences's recent earnings performance, and Sellas Life Sciences's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar